I-Mab (NASDAQ:IMAB – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect I-Mab to post earnings of ($0.12) per share for the quarter.
I-Mab Price Performance
Shares of NASDAQ IMAB opened at $0.90 on Thursday. I-Mab has a 12 month low of $0.76 and a 12 month high of $2.00. The stock has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.07.
Analyst Ratings Changes
Several brokerages recently commented on IMAB. Brookline Capital Management upgraded I-Mab to a “strong-buy” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of I-Mab in a research report on Friday, November 15th.
I-Mab Company Profile
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Read More
- Five stocks we like better than I-Mab
- How to start investing in penny stocks
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Where Do I Find 52-Week Highs and Lows?
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Stock Market Sectors: What Are They and How Many Are There?
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.
